These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
359 related articles for article (PubMed ID: 33721151)
1. Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib. Galvin R; Watson AL; Largaespada DA; Ratner N; Osum S; Moertel CL Curr Oncol Rep; 2021 Mar; 23(4):45. PubMed ID: 33721151 [TBL] [Abstract][Full Text] [Related]
2. Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. Dombi E; Baldwin A; Marcus LJ; Fisher MJ; Weiss B; Kim A; Whitcomb P; Martin S; Aschbacher-Smith LE; Rizvi TA; Wu J; Ershler R; Wolters P; Therrien J; Glod J; Belasco JB; Schorry E; Brofferio A; Starosta AJ; Gillespie A; Doyle AL; Ratner N; Widemann BC N Engl J Med; 2016 Dec; 375(26):2550-2560. PubMed ID: 28029918 [TBL] [Abstract][Full Text] [Related]
3. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas. Armstrong AE; Belzberg AJ; Crawford JR; Hirbe AC; Wang ZJ BMC Cancer; 2023 Jun; 23(1):553. PubMed ID: 37328781 [TBL] [Abstract][Full Text] [Related]
5. Current status of MEK inhibitors in the treatment of plexiform neurofibromas. Gross AM; Dombi E; Widemann BC Childs Nerv Syst; 2020 Oct; 36(10):2443-2452. PubMed ID: 32607696 [TBL] [Abstract][Full Text] [Related]
6. Combining SOS1 and MEK Inhibitors in a Murine Model of Plexiform Neurofibroma Results in Tumor Shrinkage. Jackson M; Ahmari N; Wu J; Rizvi TA; Fugate E; Kim MO; Dombi E; Arnhof H; Boehmelt G; Düchs MJ; Long CJ; Maier U; Trapani F; Hofmann MH; Ratner N J Pharmacol Exp Ther; 2023 May; 385(2):106-116. PubMed ID: 36849412 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of YAP Sensitizes the Selumetinib Treatment for Neurofibromatosis Type 1 Related Plexiform Neurofibroma. Tian Z; You Y; Xiao M; Liu J; Xu G; Ma C; Du Z; Wang Y Int J Med Sci; 2023; 20(1):125-135. PubMed ID: 36619222 [No Abstract] [Full Text] [Related]
9. A Review of Selumetinib in the Treatment of Neurofibromatosis Type 1-Related Plexiform Neurofibromas. Anderson MK; Johnson M; Thornburg L; Halford Z Ann Pharmacother; 2022 Jun; 56(6):716-726. PubMed ID: 34541874 [TBL] [Abstract][Full Text] [Related]
10. Selumetinib in Children with Inoperable Plexiform Neurofibromas. Gross AM; Wolters PL; Dombi E; Baldwin A; Whitcomb P; Fisher MJ; Weiss B; Kim A; Bornhorst M; Shah AC; Martin S; Roderick MC; Pichard DC; Carbonell A; Paul SM; Therrien J; Kapustina O; Heisey K; Clapp DW; Zhang C; Peer CJ; Figg WD; Smith M; Glod J; Blakeley JO; Steinberg SM; Venzon DJ; Doyle LA; Widemann BC N Engl J Med; 2020 Apr; 382(15):1430-1442. PubMed ID: 32187457 [TBL] [Abstract][Full Text] [Related]
11. Plexiform neurofibroma: shedding light on the investigational agents in clinical trials. Acar S; Armstrong AE; Hirbe AC Expert Opin Investig Drugs; 2022 Jan; 31(1):31-40. PubMed ID: 34932916 [TBL] [Abstract][Full Text] [Related]
12. Precision oncology in neurofibromatosis type 1: quantification of differential sensitivity to selumetinib in plexiform neurofibromas using single-cell RNA sequencing. Bhandarkar AR; Bhandarkar S; Babovic-Vuksanovic D; Raghunathan A; Schwartz J; Spinner RJ J Neurooncol; 2024 Aug; 169(1):147-153. PubMed ID: 38739187 [TBL] [Abstract][Full Text] [Related]
13. Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review. Solares I; Viñal D; Morales-Conejo M; Rodriguez-Salas N; Feliu J ESMO Open; 2021 Aug; 6(4):100223. PubMed ID: 34388689 [TBL] [Abstract][Full Text] [Related]
15. The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities. Klesse LJ; Jordan JT; Radtke HB; Rosser T; Schorry E; Ullrich N; Viskochil D; Knight P; Plotkin SR; Yohay K Oncologist; 2020 Jul; 25(7):e1109-e1116. PubMed ID: 32272491 [TBL] [Abstract][Full Text] [Related]
16. Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas: A plain language summary of SPRINT. Gross AM; Achée C; Hart SE; Brewer L; Baldwin A; Wolters PL; Widemann BC; Future Oncol; 2024 May; 20(14):877-890. PubMed ID: 38869947 [TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas. Schalkwijk S; Zhou L; Cohen-Rabbie S; Jain L; Freshwater T; So K; He Z; Gioni I; Tomkinson H; Vishwanathan K; Zhou D Cancer Chemother Pharmacol; 2021 Aug; 88(2):189-202. PubMed ID: 33903938 [TBL] [Abstract][Full Text] [Related]
18. Concomitant variants in NF1, LZTR1 and GNAZ genes probably contribute to the aggressiveness of plexiform neurofibroma and warrant treatment with MEK inhibitor. Cohen-Barak E; Toledano-Alhadef H; Danial-Farran N; Livneh I; Mwassi B; Hriesh M; Zagairy F; Gafni-Amsalem C; Bashir H; Khayat M; Warrour N; Sher O; Marom D; Postovsky S; Dujovny T; Ziv M; Shalev SA Exp Dermatol; 2022 May; 31(5):775-780. PubMed ID: 34913528 [TBL] [Abstract][Full Text] [Related]
20. Selumetinib: the first ever approved drug for neurofibromatosis-1 related inoperable plexiform neurofibroma. Mukhopadhyay S; Maitra A; Choudhury S Curr Med Res Opin; 2021 May; 37(5):789-794. PubMed ID: 33683166 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]